Combination of Hua Shi Bai Du granule (Q-14) and standard care in the treatment of patients with coronavirus disease 2019 (COVID-19): A single-center, open-label, randomized controlled trial
Jia Liu(China Academy of Chinese Medical Sciences), Luqi Huang(Shenyang Pharmaceutical University), Jinliang Yang(Chinese Academy of Medical Sciences & Peking Union Medical College), Yongjun Bian(Chinese Academy of Medical Sciences & Peking Union Medical College), Huaxin Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Wensheng Qi(Chinese Academy of Medical Sciences & Peking Union Medical College), Ming Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Suping Chen(Soochow University), Wei Yang(Chinese Academy of Medical Sciences & Peking Union Medical College), Wenliang Lv(Chinese Academy of Medical Sciences & Peking Union Medical College), Luxing Leng(Chinese Academy of Medical Sciences & Peking Union Medical College), Bing Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Haoning Zhu(Chinese Academy of Medical Sciences & Peking Union Medical College), Chunyan Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Zhixu Yang(Chinese Academy of Medical Sciences & Peking Union Medical College), Yongyue Xian(Chinese Academy of Medical Sciences & Peking Union Medical College), Jiaheng Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Ryan Zhenqi Zhou(Chinese Academy of Medical Sciences & Peking Union Medical College), Lianguo Ruan(Chinese Academy of Medical Sciences & Peking Union Medical College), Bei Yan(Ningxia Medical University), Yue Liu(Nanjing Drum Tower Hospital), Jing Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Hao Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Gang Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Bin Li(First Affiliated Hospital of Henan University), Dongxu Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Wei Wang(Sun Yat-sen University), Yingying Chen, Li Zhang, Xiaodong Cong(Chinese Academy of Medical Sciences & Peking Union Medical College), Jing Guo(State Key Laboratory of Diagnosis and Treatment of Infectious Diseases), Qing Miao(Chinese Academy of Medical Sciences & Peking Union Medical College), Jian Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Yang Chen(Science for Life Laboratory), Jianxin Jiang(Chinese Academy of Medical Sciences & Peking Union Medical College), Xin Shen(Chinese Academy of Medical Sciences & Peking Union Medical College), Lanping Guo(Chinese Academy of Medical Sciences & Peking Union Medical College), Chen Zhao(Chinese Academy of Medical Sciences & Peking Union Medical College), Guoju Dong(Chinese Academy of Medical Sciences & Peking Union Medical College), Cheng Lü(Chinese Academy of Medical Sciences & Peking Union Medical College), Lijie Hu(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaolei Xie(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 71
Related Papers
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
|The Lancet|2020|51.8k
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
|New England Journal of Medicine|2020|5.5k
A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)
|Military Medical Research|2020|2.4k
Targeting PI3K/Akt signal transduction for cancer therapy
|Signal Transduction and Targeted Therapy|2021|1.7k
Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US
|JAMA Internal Medicine|2020|1k